Paper Details

  1. Home
  2. Paper Details

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.

Author: BassaAyesha, HillAndrew, KumarSushma, MngqibisaRosie, NelsonMark, OrkinChloe, RassoolMohammed, RodgersAnthony, TealValerie, TepplerHedy, WinstonAlan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Switching from an efavirenz-based regimen to a doravirine-based regimen did not significantly improve CNS toxicities attributable to efavirenz, but maintained virologic efficacy and improved lipid profiles.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Doravirine is an alternative treatment option for individuals who do not tolerate efavirenz. We assessed efficacy, safety, and CNS effects in adults with HIV-1 and CNS complaints who switched from an efavirenz-based regimen to a doravirine-based regimen. DESIGN: Multicenter, double-blind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33587439

データ提供：米国国立医学図書館（NLM）

Doravirine: A Safer Alternative for HIV Treatment?

The journey to manage HIV is often filled with challenges and side effects. This study explores a potential safer alternative for individuals struggling with the side effects of efavirenz, a common HIV medication. The researchers compared the efficacy and safety of switching from an efavirenz-based regimen to a doravirine-based regimen in individuals experiencing central nervous system (CNS) complaints. This is like finding a new path in the desert, offering a potentially smoother and less burdensome journey for those living with HIV.

Switching Regimens: A Potential for Improved CNS Tolerability

The study found that switching to doravirine did not significantly improve CNS toxicity compared to staying on efavirenz. However, doravirine did maintain virologic suppression and improved lipid profiles. This suggests that while it might not be a complete solution for CNS side effects, doravirine could be a valuable alternative for individuals seeking to manage these issues. This is like finding a slightly different path in the desert, offering a potentially more comfortable journey with similar destination.

HIV Treatment: A Quest for Better Options

This study emphasizes the ongoing quest for safer and more effective treatment options for HIV. This research highlights the importance of exploring alternative medications and treatment strategies to improve the lives of individuals living with HIV. It's a testament to the unwavering dedication of medical professionals to find better solutions for those facing this challenging condition.

Dr.Camel's Conclusion

This research sheds light on the potential of doravirine as an alternative treatment option for individuals who do not tolerate efavirenz. While further research is needed to fully understand the long-term effects and potential benefits of switching to doravirine, this study offers promising insights into the pursuit of safer and more effective HIV treatment options.

Date :
  1. Date Completed 2021-04-27
  2. Date Revised 2023-09-21
Further Info :

Pubmed ID

33587439

DOI: Digital Object Identifier

00002030-202104010-00006

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.